d1e30690_dic_NECT___Inclusion_completed__Cancer_type
[Title] An open-label, non-randomised, multicentre phase 1/2 trial of RO5424802 given orally to non-small cell lung cancer patients who have ALK mutation and failed crizotinib treatment. [Country] SE [Cancer type] 
Head and Neck cancer
Nordic NECT - Inclusion completed
Cancer type